NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

RXRX

RXRX US Stock
$35.1
Open: $32.27 High: $32.435 Low: $26.9 Close: $28.07
Range: 2021-05-06 - 2021-05-07
Volume: 380,786
Market: Closed
Powered by Finage Stock APIDelayed data
RXRX
  • CEO:
  • Employees:
  • Sector:
  • Industry:
RXRX News
Latest news about the RXRX
  • 2 Hot Biotech IPOs to Consider

    Especially for companies that are expected to be growing right out of the gate, getting in during the market's initial feeding frenzy sometimes means buying a stock when it's as cheap as it will ever be. In this vein, Recursion Pharmaceuticals (NASDAQ: RXRX) and Biomea Fusion (NASDAQ: BMEA) are a pair of biotechs that had their IPOs last week, and both have unique value for investors that could make them worth a (speculative) buy. Recursion's information technology-heavy approach to drug discovery could make it a rising star on the basis of its already extensive list of development collaborations alone.

    View More →
  • Recursion Pharmaceuticals Announces Closing of Initial Public Offering

    Recursion Pharmaceuticals, Inc. ("Recursion" or "we") announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the exercise in full of the underwriters' option to purchase 3,636,363 additional shares of its Class A common stock, at a price to the public of $18.00 per share. Including the option exercise, the gross proceeds from the offering were $501.8 million, before deducting underwriting discounts and commissions and other offering expenses payable by Recursion. All of the shares were offered by Recursion. The shares began trading on the Nasdaq Global Select Market on April 16, 2021 under the symbol "RXRX."

    View More →
  • 3 Biotech Stocks Started Trading Today. What to Know About Each.

    Recursion Pharmaceutical, Akoya Biosciences, and Biomea Fusion listed their shares on Friday. Recursion and Biomea are biotechnology firms, while Akoya provides technology to biotechs.

    View More →
  • Recursion Pharmaceuticals Announces Pricing of Initial Public Offering

    Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Recursion, are expected to be $436.4 million, excluding any exercise of the underwriters' option to purchase additional shares. The shares are expected to begin trading on the Nasdaq Global Select Market on April 16, 2021 under the symbol "RXRX" and the offering is expected to close on April 20, 2021, subject to customary closing conditions. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an additional 3,636,363 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

    View More →